Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Asset disposition
Credit agrmnt [a]
Director departure
Inv. presentation
Quarterly results
Acq. announced

PERNIX THERAPEUTICS HOLDINGS, INC. (PTX) Create: Alert

All | News | Filings
Date FiledTypeDescription
09/25/2019 15-12B Form 15-12B - Securities registration termination [Section 12(b)]:
06/26/2019 8-K Quarterly results
05/21/2019 8-K Asset disposition
05/14/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
05/07/2019 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Initial Monthly Operating Report"
05/06/2019 8-K Completion of Acquisition or Disposition of Assets
04/19/2019 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Amended and Restated Asset Purchase Agreement, by and among Pernix Therapeutics Holdings, Inc. and Currax Holdings LLC"
04/02/2019 25-NSE Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities:
04/01/2019 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
02/27/2019 8-K Quarterly results
02/19/2019 8-K Quarterly results
02/19/2019 GN Pernix Therapeutics Holdings, Inc. Enters into Asset Purchase Agreement with Certain Funds Managed by Highbridge Capital Management
02/13/2019 SC 13G/A RENAISSANCE TECHNOLOGIES LLC reports a 7.9% stake in PERNIX THERAPEUTICS HOLDINGS, INC.
01/08/2019 4 Pina Kenneth (SVP, GC,Compliance Off & Sec) has filed a Form 4 on PERNIX THERAPEUTICS HOLDINGS, INC.
Txns: Paid exercise price by delivering 417 shares @ $0.449, valued at $187.2
11/21/2018 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Mr. John A. Sedor C/O Pernix Thereapeutics Holdings, Inc. 10 North Park Place, Suite 201 Morristown, NJ 07960"
11/13/2018 GN Detailed Research: Economic Perspectives on Pernix Therapeutics, Hallador Energy, Vince Holding, Tuesday Morning, Information Services Group, and Sienna Biopharmaceuticals — What Drives Growth in Today's Competitive Landscape
11/09/2018 10-Q Quarterly Report for the period ended September 30, 2018
11/02/2018 GN Pernix Therapeutics to Report Third Quarter 2018 Financial Results on Thursday, November 8
10/31/2018 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
10/22/2018 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
10/09/2018 8-K/A Quarterly results
09/12/2018 GN Pernix Therapeutics Holdings, Inc.'s Subsidiaries File Notice of Appeal in Patent Litigation Concerning Zohydro® ER with BeadTek®
08/27/2018 8-K Other Events, Financial Statements and Exhibits
Docs: "Pernix Therapeutics Announces Ruling in Patent Litigation Concerning Zohydro® ER with BeadTek®"
08/27/2018 GN Pernix Therapeutics Announces Ruling in Patent Litigation Concerning Zohydro® ER with BeadTek®
08/22/2018 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
08/10/2018 4 Pina Kenneth (SVP, GC & Compliance Off.) has filed a Form 4 on PERNIX THERAPEUTICS HOLDINGS, INC.
Txns: Paid exercise price by delivering 411 shares @ $1.86, valued at $764.5
08/10/2018 4 Whaley Glenn (VP of Fin, PAO & Controller) has filed a Form 4 on PERNIX THERAPEUTICS HOLDINGS, INC.
Txns: Paid exercise price by delivering 84 shares @ $1.86, valued at $156.2
08/10/2018 4 Sedor John A (Chairman of Board and CEO) has filed a Form 4 on PERNIX THERAPEUTICS HOLDINGS, INC.
Txns: Paid exercise price by delivering 685 shares @ $1.86, valued at $1.3k
08/10/2018 4 Smith Angus W. (SVP, CBO & Principal Fin Off) has filed a Form 4 on PERNIX THERAPEUTICS HOLDINGS, INC.
Txns: Paid exercise price by delivering 282 shares @ $1.86, valued at $524.5
08/09/2018 10-Q Quarterly Report for the period ended June 30, 2018
08/09/2018 8-K Quarterly results
Docs: "Pernix Therapeutics Reports Second Quarter 2018 Financial Results"
08/09/2018 GN Pernix Therapeutics Reports Second Quarter 2018 Financial Results
08/01/2018 SC 13G Flynn James E reports a 9.2% stake in Pernix Therapeutics Holdings, Inc.
08/01/2018 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E...
Docs: "Form of Articles Supplementary for 0% Series C Perpetual Convertible Preferred Stock",
"Form of Exchange Agreement, by and among Pernix Therapeutics Holdings, Inc., Deerfield Management L.P. and certain of its affiliates",
"The exchange of approximately $2.7 million aggregate principal amount of Senior Secured Notes by the Exchange Holders for 1,204,739 shares of Common Stock, which includes accrued and unpaid interest on the Senior Secured Notes; and",
"The exchange of approximately $2.7 million aggregate principal amount of Senior Secured Notes by the Exchange Holders for 1,204,739 shares of Common Stock, which includes accrued and unpaid interest on the Senior Secured Notes; and",
"Form of Amendment No. 3 to the ABL Facility, August 1, 2018, by and among Pernix, the guarantors and lenders party thereto and Cantor Fitzgerald Securities, as agent",
"Form of Amendment No. 2 to the Term Facility, by and among PIP DAC, the lenders party thereto and Cantor Fitzgerald Securities, as agent",
"Pernix Therapeutics Announces a Series of Transactions To Strengthen Its Balance Sheet and Improve Financial Flexibility MORRISTOWN, N.J. – August 1, 2018 – Pernix Therapeutics Holdings, Inc. , a specialty pharmaceutical company, announces a series of transactions aimed at strengthening its balance sheet and improving financial flexibility, as described below. Exchange Agreement Pernix entered into exchange agreements with certain holders of Pernix’ s outstanding 12% Senior Secured Notes due 2020 for newly issued shares of common stock and shares of a newly created class of convertible preferred stock, the terms of which are described below . These transactions , are expected to close on August 1, 2018. The Exchange Transactions include:"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy